List of Ponvory drug patents

Ponvory is owned by Janssen Pharms.

Ponvory contains Ponesimod.

Ponvory has a total of 5 drug patents out of which 0 drug patents have expired.

Ponvory was authorised for market use on 18 March, 2021.

Ponvory is available in tablet;oral dosage forms.

Ponvory can be used as treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults using a dose titration schedule followed by a maintenance dose, reduction of circulating lymphocytes in treating relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults, treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Drug patent challenges can be filed against Ponvory from 2025-03-18.

The generics of Ponvory are possible to be released after 10 December, 2035.

PONVORY's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE43728 JANSSEN PHARMS Thiazolidin-4-one derivatives
Nov, 2024

(1 year, 7 months from now)

US9062014 JANSSEN PHARMS Crystalline forms of (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-0-tolyl-thiazolidin-4-one
May, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9000018 JANSSEN PHARMS Thiazolidin-4-one-derivatives
Nov, 2024

(1 year, 7 months from now)

US8273779 JANSSEN PHARMS Thiazolidin 4-one derivatives
Dec, 2025

(2 years from now)

US10220023 JANSSEN PHARMS Dosing regimen for a selective S1P1 receptor agonist
Dec, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 18, 2026

Drugs and Companies using PONESIMOD ingredient

NCE-1 date: 2025-03-18

Market Authorisation Date: 18 March, 2021

Treatment: Reduction of circulating lymphocytes in treating relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive dise...

Dosage: TABLET;ORAL

More Information on Dosage

PONVORY family patents

18

United States

12

European Union

8

Korea, Republic of

7

Japan

5

Israel

5

Australia

4

China

4

Canada

3

South Africa

3

Denmark

3

Mexico

3

Slovenia

3

Morocco

3

Brazil

3

Croatia

3

Portugal

3

Malaysia

3

Spain

3

Poland

3

Chile

3

Taiwan, Province of China

EA

3

EA

2

Hong Kong

2

Russia

2

Lithuania

2

Hungary

2

Philippines

2

Norway

2

Singapore

2

Argentina

2

Cyprus

2

Ukraine

2

New Zealand

IB

1

IB

1

Austria

1

Saudi Arabia

1

Germany

1

Netherlands

1

RS

1

United Kingdom

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in